Drug
Piperaquine clinical trials
- studies test it
- 94
- open now
- 7
- in phase 3
- 36
- first study started
- 2003
Keep track of what changes. Save the piperaquine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
- DP
- 6
Studies by the year they started
94 studies that test it; most in 2010 (9)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 3 |
| 2012 | 7 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 7
- Phase 3
- 36
- Phase 4
- 30
- No phase
- 14
What it is tested for
Each study’s main condition, where its own words name it.
- Malaria
- 57
Who runs them
Industry 5 · Other 89
University of Oxford (9) · University of California, San Francisco (7) · London School of Hygiene and Tropical Medicine (7) · Liverpool School of Tropical Medicine (6) · Medicines for Malaria Venture (5) · National Institute for Medical Research, Tanzania (4) · Radboud University Medical Center (3) · sigma-tau i.f.r. S.p.A. (3)
Often tested with
Tested in the same studies.
Artenimol (83) · Fanasil, pyrimethamine drug combination (13) · Artemether, Lumefantrine Drug Combination (11) · Amodiaquine (8) · Chloroquine (6) · Primaquine (5) · Artesunate (5) · Artefenomel (2)
Studies
Open first, then newest update. How each study uses piperaquine is read from its arms, and is right about nine times in ten.
Testing it · 94
- Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community TransmissionNot yet recruitingPhase 4University of California, San FranciscoNCT07246525Written as dihydroartemisinin-piperaquine
- Focal Mass Drug Administration for the Prevention of Malaria in PregnancyRecruitingEarly Phase 1University of North Carolina, Chapel HillNCT07021430Written as Dihydroartemisinin Piperaquine
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy AdultsNot yet recruitingPhase 1University of OxfordNCT07470424Written as Piperaquine
- Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium VivaxNot yet recruitingNot applicableWalter Reed Army Institute of Research (WRAIR)NCT07533136Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Perennial Malaria Chemoprevention in the Malaria Vaccine EraNot yet recruitingPhase 4Stanford UniversityNCT07322068Written as Dihydroartemisinin Piperaquine
- Safety of Antimalarials in the FIRst trimEsterRecruitingPhase 3Liverpool School of Tropical MedicineNCT06962319Written as dihydroartemisinin-piperaquine (DP)
- Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina FasoRecruitingPhase 3Malaria ConsortiumNCT05946642Written as Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM)
- IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe FloodingActive, not recruitingNot applicableUniversity of North Carolina, Chapel HillNCT06870344Written as Dihydroartemisinin piperaquine
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, MalawiCompletedPhase 4Liverpool School of Tropical MedicineNCT06083688Written as Dihydroartemisinin-Piperaquine
- The Transmission of Artemisinin Resistant Parasites Before and After Conventional Artemisinin-combination TherapyCompletedPhase 4Infectious Diseases Research Collaboration, UgandaNCT06347471Written as Dihydroartemisinin-Piperaquine
- Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP)Active, not recruitingPhase 3Grant Dorsey, M.D, Ph.D.NCT04978272Written as Dihydroartemisinin-piperaquine (DP)
- Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of AntimalarialsActive, not recruitingPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT04009343Written as Dihydroartemisinin-piperaquine
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in UgandaCompletedPhase 3Grant Dorsey, M.D, Ph.D.NCT04336189Written as Dihydroartemisinin-piperaquine (DP)
- In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in MozambiqueCompletedPhase 4Centro de Investigacao em Saude de ManhicaNCT05343312Written as DHP
- Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in PregnancyActive, not recruitingPhase 3Menzies School of Health ResearchNCT05426434Written as Dihydroartemisinin-Piperaquine (DP)
- Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, EthiopiaActive, not recruitingPhase 3PATHNCT06516042Written as Dihydroartemisinin-piperaquine
- Dihydroartemisinin-Piperaquine in the Context of Antiretroviral TherapyCompletedPhase 4University of California, San FranciscoNCT04487145Written as Dihydroartemisinin-piperaquine
- Boosting the Impact of SMC Through Simultaneous Screening and Treatment of RoommatesCompletedPhase 4Institut de Recherche en Sciences de la Sante, Burkina FasoNCT04816461Written as Dihydroartemisinin-Piperaquine
- Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in TanzaniaCompletedPhase 3National Institute for Medical Research, TanzaniaNCT03640403Written as Dihydroartemisinin-piperaquine
- Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihydroartemisinin-piperaquine on Reducing Malaria Burden in School Aged Children in TanzaniaCompletedPhase 4National Institute for Medical Research, TanzaniaNCT04245033Written as Dihydroartemisinin-Piperaquine (DP)
See all 94 studies that test piperaquine →
Given in every arm · 11 — piperaquine is usual care beside what is tested
- Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated MalariaNot yet recruitingPhase 4Curtin UniversityNCT07403643Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)CompletedPhase 2London School of Hygiene and Tropical MedicineNCT04609098Written as Dihydroartemisinin/Piperaquine
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlStatus unknownPhase 3London School of Hygiene and Tropical MedicineNCT04844905Written as Dihydroartemisinin-piperaquine
- Malaria Elimination Pilot Study in Military Forces in CambodiaStatus unknownPhase 4Armed Forces Research Institute of Medical Sciences, ThailandNCT02653898Written as DHA-PIP
- Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in CambodiaCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT02612545Written as Dihydroartemisinin-piperaquine (DHA-PPQ)
- Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to MosquitosTerminatedPhase 1Novartis PharmaceuticalsNCT02543086Written as Piperaquine Phosphate
- Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding StudyCompletedPhase 2Liverpool School of Tropical MedicineNCT02511353Written as dihydroartemisinin-piperaquine
- Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic CarriersCompletedPhase 3London School of Hygiene and Tropical MedicineNCT01838902Written as DHA-PPQ
- Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in MalawiStatus unknownPhase 3Kamuzu University of Health SciencesNCT02721420Written as dihydroartemisinin-piperaquine
- Safety and Tolerability of Low Dose PrimaquineCompletedPhase 4Malaria ConsortiumNCT02434952Written as Dihydroartemisinin piperaquine (DHA PP)
- Phase2a Primaquine Dose Escalation StudyCompletedPhase 2University of California, San FranciscoNCT01743820Written as dihydroartemisinin-piperaquine
As the comparator · 7 — what is tested is compared with piperaquine
- Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West PapuaCompletedPhase 2Syamsudin Abdillah,Ph.D, Pharm DNCT06036030Written as Piperaquine
- Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum MalariaCompletedPhase 1HuLowNCT02614404Written as Dihydroartemisinin-piperaquine
- Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum TransmissionCompletedPhase 2/3London School of Hygiene and Tropical MedicineNCT04049916Written as Dihydroartemisinin/Piperaquine
- Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesStatus unknownPhase 2Nurex S.r.l.NCT03697668Written as Dihydroartemisinin-piperaquine
- Safety, Tolerability, Pharmacokinetics and Efficacy of ARCOCompletedPhase 4Ifakara Health InstituteNCT01930331Written as dihydroartemisinin/piperaquine phosphate
- Phase 2 Efficacy Study of Primaquine and Methylene BlueCompletedPhase 2University of California, San FranciscoNCT02831023Written as Dihydroartemisinin-piperaquine
- Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:CompletedPhase 4Institut Pasteur, CambodiaNCT02118090Written as DHA-PP
Codes
What other systems call piperaquine · ClinicalTrials.gg INT003036
- MeSH (NLM) C034759piperaquineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) A0HV2Q956YPIPERAQUINEConfirmed FDA, NLM, Wikidata
- Wikidata Q7197338piperaquineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87634PiperaquineOne source FDA
- DrugBank DB13941One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C034759 | piperaquine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | A0HV2Q956Y | PIPERAQUINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7197338 | piperaquine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87634 | Piperaquine | One source FDA |
| DrugBank | DB13941 | — | One source Wikidata |
Also registered as piperaquine monophosphate (UNII 5A17BAT3GK), piperaquine phosphate (UNII IHB5WLO51Q) and piperaquine phosphate tetrahydrate (UNII 854D7K8LXB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.